171 related articles for article (PubMed ID: 12543654)
21. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
[TBL] [Abstract][Full Text] [Related]
23. Emergence of High-level Gentamicin Resistance among
Labibzadeh M; Kaydani GA; Savari M; Ekrami A
Pol J Microbiol; 2018; 67(4):401-406. PubMed ID: 30550226
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
25. Reduced susceptibility of Enterococcus spp. isolates from Cairo University Hospital to tigecycline: Highlight on the influence of proton pump inhibitors.
Hassan RM; Ghaith DM; Ismail DK; Zafer MM
J Glob Antimicrob Resist; 2018 Mar; 12():68-72. PubMed ID: 29274469
[TBL] [Abstract][Full Text] [Related]
26. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
Henwood CJ; Gatward T; Warner M; James D; Stockdale MW; Spence RP; Towner KJ; Livermore DM; Woodford N
J Antimicrob Chemother; 2002 Mar; 49(3):479-87. PubMed ID: 11864948
[TBL] [Abstract][Full Text] [Related]
27. Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark.
Aarestrup FM; Agerso Y; Gerner-Smidt P; Madsen M; Jensen LB
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):127-37. PubMed ID: 10863107
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
30. Typing of Enterococcus spp. strains in 4 hospitals in the Małopolska region in Poland.
Talaga K; Odrowąż-Konduracka D; Paradowska B; Jagiencarz-Starzec B; Wolak Z; Bulanda M; Szczypta A
Adv Clin Exp Med; 2018 Jan; 27(1):111-117. PubMed ID: 29521051
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of vancomycin-resistant enterococci in relation to the administration of glycopeptide antibiotics.
Kolár M; Vágnerová I; Látal T; Kohnová I
Acta Univ Palacki Olomuc Fac Med; 1999; 142():69-71. PubMed ID: 10743728
[TBL] [Abstract][Full Text] [Related]
32. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
33. Tigecycline: a glycylcycline antimicrobial agent.
Doan TL; Fung HB; Mehta D; Riska PF
Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
[TBL] [Abstract][Full Text] [Related]
34. A Nosocomial Cluster of Tigecycline- and Vancomycin-Resistant
Bender JK; Klare I; Fleige C; Werner G
Microb Drug Resist; 2020 Jun; 26(6):576-582. PubMed ID: 31895641
[TBL] [Abstract][Full Text] [Related]
35. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.
Jones RN
Diagn Microbiol Infect Dis; 1999 Nov; 35(3):249-52. PubMed ID: 10626138
[TBL] [Abstract][Full Text] [Related]
36. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
Namdari H; Tan TY; Dowzicky MJ
Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
[TBL] [Abstract][Full Text] [Related]
37. Emergence and epidemiology of vancomycin-resistant enterococci in Australia.
Bell J; Turnidge J; Coombs G; O'Brien F
Commun Dis Intell; 1998 Oct; 22(11):249-52. PubMed ID: 9823687
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect.
Noviello S; Ianniello F; Leone S; Fiore M; Esposito S
J Chemother; 2008 Oct; 20(5):577-80. PubMed ID: 19028619
[TBL] [Abstract][Full Text] [Related]
39. Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
Starzengruber P; Thriemer K; Haque R; Khan WA; Fuehrer HP; Siedl A; Hofecker V; Ley B; Wernsdorfer WH; Noedl H
Antimicrob Agents Chemother; 2009 Sep; 53(9):4040-2. PubMed ID: 19596882
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial susceptibility of enterococci recovered from healthy cattle, pigs and chickens in nine EU countries (EASSA Study) to critically important antibiotics.
de Jong A; Simjee S; Garch FE; Moyaert H; Rose M; Youala M; Dry M;
Vet Microbiol; 2018 Mar; 216():168-175. PubMed ID: 29519512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
